Mesenchymal stem cell therapy (Promethera Biosciences)

N/A

Report date: 2025/07/01 20:00:14

Base Information

Drug NameMesenchymal stem cell therapy (Promethera Biosciences)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsCrigler-Najjar SyndromeUrea Cycle Disorders, InbornAcute-On-Chronic Liver Failure
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumItalyUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPromethera Biosciences LlcCatholic University Of Louvain
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCellaion SA
Active IndicationsN/A
Inactive IndicationsCrigler-Najjar SyndromeUrea Cycle Disorders, InbornAcute-On-Chronic Liver Failure

Other Information

ATC CodeN/A
Related LinksN/A